Prostate Cancer Clinical Trial

Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery

Summary

RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Ixabepilone may also make tumor cells more sensitive to radiation therapy. Giving radiation therapy with chemotherapy after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase I/II trial is studying the side effects and best dose of ixabepilone when given together with radiation therapy to see how well it works in treating patients with high-risk stage III prostate cancer after surgery.

View Full Description

Full Description

OBJECTIVES:

Primary

To determine the maximum-tolerated dose and dose-limiting toxicity of ixabepilone in combination with concurrent intensity-modulated radiation therapy in patients with high-risk prostate cancer after prostatectomy. (Phase I)
To determine the toxicity profile of this regimen in these patients. (Phase I)

Secondary

To assess freedom from progression in patients treated with this regimen. (Phase II)
To assess biochemical failure, local failure, and distant failure in patients treated with this regimen. (Phase II)
To assess disease-specific survival and overall survival of patients treated with this regimen. (Phase II)
To evaluate acute and late toxicity of this regimen in these patients.

OUTLINE: This is a phase I, dose-escalation study of ixabepilone followed by a phase II study.

Patients undergo adjuvant intensity-modulated radiation therapy once daily, 5 days a week, for 7-9 weeks. Patients also receive concurrent ixabepilone IV over 1 hour on days 1 and 8. Treatment with ixabepilone repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up every 3 months for 1 year, every 6 months for 3 years, and then annually for 6 years.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Diagnosis of adenocarcinoma of the prostate

Must have undergone any common form of prostatectomy (e.g., open, perineal, laparoscopic, or robotic) within the past 2 years
T3 disease or positive surgical margins
Node negative (N0) and free of distant metastasis (M0) by a bone scan and CT scan or MRI of the pelvis within the past 90 days
Considered high-risk disease
Gleason score = 7 and post-operative PSA > 0 and ≤ 2 ng/mL OR Gleason score ≥ 8 and post-operative PSA ≥ 0 and ≤ 2 ng/mL

Pre-prostatectomy PSA available

Range of pre-prostatectomy PSA values not required

PATIENT CHARACTERISTICS:

Zubrod (ECOG) performance status 0-1
ANC ≥ 2,000/mm^3
Platelet count ≥ 100,000/mm^3
Hemoglobin ≥ 8 g/dL
Total bilirubin < 1.5 times upper limit of normal (ULN)
AST and ALT < 2.5 times ULN
Alkaline phosphatase < 2.5 times ULN
Fertile patients must use effective contraception during and for 4 weeks after completion of study therapy
Patients with urinary incontinence waiting for stabilization of urinary function after prostatectomy allowed for up to 6 months
No CTCv4 peripheral neuropathy (motor or sensory) ≥ grade 1
No history of inflammatory colitis including Crohn disease or ulcerative colitis
No significant history of psychiatric illness
No other invasive malignancy within the past 3 years except adequately treated nonmelanoma skin cancer or carcinoma in situ of the oral cavity

No severe, active co-morbidity with any of the following:

Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months
Transmural myocardial infarction within the past 6 months
Acute bacterial or fungal infection requiring IV antibiotics
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days

Immunocompromised patients or AIDS based upon current CDC definition

HIV testing not required
No history of hypersensitivity reactions to agents containing Cremophor® EL or its derivatives (e.g., polyoxyethylated castor oil)

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
No prior pelvic radiotherapy or radiotherapy for another malignancy that encompasses ≥ 30% of major bone marrow-containing areas (e.g., pelvis or lumbar spine)

No prior hormonal therapy for prostate cancer

Prior hormonal agents, e.g., finasteride or dutasteride, for benign prostatic hypertrophy allowed

No other concurrent adjuvant antineoplastic therapy planned while on this protocol, including the following:

Cryotherapy
Hormonal therapy

Other chemotherapy for prostate cancer

Prior chemotherapy for a different type of cancer allowed provided it was administered > 3 years ago

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Study ID:

NCT01079793

Recruitment Status:

Withdrawn

Sponsor:

University of Texas Southwestern Medical Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas Texas, 75390, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Study ID:

NCT01079793

Recruitment Status:

Withdrawn

Sponsor:


University of Texas Southwestern Medical Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider